**Sir**,

I read with interest the recent paper by [@bib4], describing the effects of neoadjuvant chemotherapy on serum complement factor expression ([@bib4]). The authors also reported increase in levels of the plasma protein inter-*α*-trypsin inhibitor (I*α*I), but they may have failed to appreciate the potential significance of this finding.

I*α*I is not an acute-phase protein, as the authors report in this paper; in fact I*α*I plasma concentration declines during acute inflammation, because of consumption and decreased liver expression ([@bib1]; [@bib5]). Moreover, I*α*I heavy chain expression is downregulated in cancers, including breast cancer ([@bib3]). Furthermore, I*α*I does not simply have hyaluronan-binding properties; it inhibits cancer metastasis ([@bib6]; [@bib7]) and has strong anti-inflammatory properties ([@bib8]). In fact, we showed that I*α*I inhibits complement activation, both through the classical and the alternative pathways ([@bib2]). Thus, the association of increased I*α*I and complement plasma levels is significant for at least two reasons. First, upregulation of I*α*I may be a regulatory mechanism inhibiting complement activation. As baseline I*α*I plasma concentration is substantial (0.1--0.5 mg ml^−1^; [@bib8]), even a modest relative increase of ∼50%, as the authors report, would mean a significant absolute increase. As the observed increase in plasma I*α*I overrides the expected acute phase decline, powerful induction mechanisms may be assumed. Second, I*α*I is now in production in the United States and will soon be tested in a clinical trial for its effect in sepsis morbidity and mortality. As complement activation appears to have a role in the response to chemotherapy, factors that affect this activation, such as I*α*I, may be interesting as therapeutic agents. Furthermore, I*α*I levels may be predictive of response to treatment as well, as they are in sepsis ([@bib5]).

In conclusion, I believe that I*α*I--complement interactions are important in the context of cancer progression and treatment, and these interactions should be highlighted in reference to the recently published paper by [@bib4].
